-
Mashup Score: 1
La Fundación Jiménez Díaz, Rey Juan Carlos, Infanta Elena y General de Villalba han mostrado su evaluación de resultados
Source: Redacción MédicaCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6
Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10…
Source: news.bms.comCategories: Cardiologists, Latest HeadlinesTweet-
@EGarciaSayan @ASE360 @JournalASEcho @Kfarooqi @NadeenFaza @boegel_kelly @DavidWienerMD @docbhardwaj @ash71us @kgzimmerman @onco_cardiology mavacamten/Camzyos initiation & treatment will be serially #EchoFirst-guided — Rx will be restricted through REMS program https://t.co/QJ7GxU5u44 #Valor used core lab-measured LVEF, LVOT gradient at rest, & Valsalva provocation will this be sufficient in real world? #ASEchoJC
-
-
Mashup Score: 1Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? - 3 year(s) ago
Abstract. In less than 2 decades, major clinical advances have been made in various areas of hematologic malignancies. Clinicians and patients now frequently fa
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematología Este fue el trabajo que me hizo cambiar mi forma de entender la actividad asistencial hacia una “medicina basada en #valor”, dando voz al #paciente y haciéndolo partícipe en la toma de decisiones #VBHC #PROMs #PREMs https://t.co/q3OZnovlYb
-
RT @UICOquironsalud: @quironsalud pone en #valor la gestión de sus hospitales en la red pública #VBHC https://t.co/y8alfy4FNh